Alvotech Raises $165 Million in Public Offering and Private Placement
Event summary
- Alvotech closed a public offering of 26,066,667 ordinary shares at $3.75 per share, raising approximately $98 million before expenses.
- Underwriters fully exercised their option to purchase additional shares, adding 3,400,000 shares to the offering.
- Concurrent private placement of 17,826,666 ordinary shares expected to raise approximately $67 million, closing by June 25, 2026.
- Total gross proceeds from both offerings amount to approximately $165 million before deducting expenses.
- Proceeds will fund biosimilar development, working capital, and general corporate purposes.
The big picture
Alvotech's successful $165 million fundraising underscores its aggressive push to solidify its position in the biosimilars market. The proceeds will fuel its development pipeline and global expansion, aligning with broader industry trends toward cost-effective biologic therapies. The involvement of major underwriters like BofA Securities, Jefferies, and Evercore ISI highlights the strategic importance of this financing round.
What we're watching
- Development Pipeline
- How Alvotech will allocate the $165 million to advance its nine disclosed biosimilar candidates and pre-commercialization activities.
- Market Expansion
- Whether the funding will accelerate Alvotech's strategic commercial partnerships in key markets like the U.S., Europe, and Asia.
- Financial Strategy
- The pace at which Alvotech will use the proceeds for acquisitions, collaborations, or repayment of indebtedness.
Related topics